LoginSignup
GUB

Gubra

Stock
Stock
ISIN: DK0062266474
Ticker: GUBRA
DK0062266474
GUBRA

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 

$9.678

CHART BY

Frequently asked questions

The market capitalization of Gubra is $799.21M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Gubra's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.726. EPS indicates the company's profitability on a per-share basis.
Currently, 5 analysts cover Gubra's stock, with a consensus target price of $82.02. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Gubra reported a revenue of $42.06M.
Gubra's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$28.54M. EBITDA measures the company's overall financial performance.
Gubra has a free cash flow of -$122.92M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Gubra employs approximately 269 people. It operates in the Health Care sector, specifically within the Miscellaneous Commercial Services industry.
The free float of Gubra is 6.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$799.21M
EPS (TTM) 
-$1.726
Free Float 
6.84M
Revenue (TTM) 
$42.06M
EBITDA (TTM) 
-$28.54M
Free Cashflow (TTM) 
-$122.92M

Pricing

1D span
$48.39$50.53
52W span
$45.60$87.45

Analyst Ratings

The price target is $82.02 and the stock is covered by 5 analysts.

Buy

4

Hold

1

Sell

0

Information

Gubra A/S engages in providing research and development services to pharmaceutical and biotechnology companies on a contract basis. It operates through two business segments: Pre-clinical Contract Research (CRO), Discovery and Partnerships (D and P), and Gubra Green. The CRO segment refers to pre-clinical contract research and development services within metabolic and fibrotic diseases. The D and P segment include portfolio strategy in the form of upfront payments, research payments, milestone payments, and royalties. The Gubra Green segment relates to investments in targeting assets. The company was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Hørsholm, Denmark.

Employees
269
Industries
Miscellaneous Commercial Services
Sector
Health Care

Identifier

ISIN
DK0062266474
Primary Ticker
GUBRA

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin